Akebia Therapeutics (AKBA) Operating Margin (2017 - 2026)

Akebia Therapeutics (AKBA) has 10 years of Operating Margin data on file, last reported at 8.77% in Q1 2026.

• Operating Margin for Q1 2026 came in at 8.77%, down 3234.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 2.28% (up 1419.0% YoY), and the FY2025 annual result was 9.95%, up 4146.0% from the prior year.
• Operating Margin improved to 8.77% in Q1 2026 per AKBA's latest filing, from 14.84% in the prior quarter.
• Over five years, Operating Margin peaked at 78.68% in Q2 2022 and troughed at 144.01% in Q1 2022.
• A 5-year average of 22.7% and a median of 15.96% in 2023 frame the typical range for Operating Margin.
• The sharpest annual moves came in 2022 and 2023: Operating Margin soared 22862 bps in 2022, then sank 9464 bps in 2023.
• A 5-year view of Operating Margin shows it stood at 8.73% in 2022, then jumped by 128 bps to 2.45% in 2023, then tumbled by 1358 bps to 30.77% in 2024, then jumped by 52 bps to 14.84% in 2025, then jumped by 41 bps to 8.77% in 2026.
• Business Quant data shows AKBA's Operating Margin at 8.77% in Q1 2026, 14.84% in Q4 2025, and 7.57% in Q3 2025.